China’s Biotech Surge Challenges U.S. Dominance

China’s biotech surge is reshaping global competition, outpacing the U.S. in clinical development and supply chains while drawing multinational firms with cost advantages and regulatory ease—though America still dominates through access to its massive healthcare market and remains more worried about domestic funding cuts than foreign rivals. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/b728d352df677dd4